Meridian Bioscience SEC Filings

Type
Report
Date
15-12G15-12G-Formular2/13/2023
10-QQuartalsbericht2/9/2023
EFFECTEFFECT-Formular2/3/2023
EFFECTEFFECT-Formular2/3/2023
EFFECTEFFECT-Formular2/3/2023
EFFECTEFFECT-Formular2/3/2023
EFFECTEFFECT-Formular2/3/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
POS AMPOS AM-Formular2/2/2023
POS AMPOS AM-Formular2/2/2023
POS AMPOS AM-Formular2/2/2023
POS AMPOS AM-Formular2/2/2023
POS AMPOS AM-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
S-8 POSS-8 POS-Formular2/2/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/1/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
25-NSE25-NSE-Formular1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
4Insidertransaktion1/31/2023
SC 13G/ABeneficial ownership report1/31/2023
10-K/A10-K/A-Formular1/27/2023
SC 13G/ABeneficial ownership report1/20/2023
SC 13D/ASC 13D/A-Formular1/10/2023
4Insidertransaktion1/9/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/12/2022
4Insidertransaktion12/7/2022
SC 13D/ASC 13D/A-Formular12/2/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/22/2022
10-KJahresbericht11/22/2022
4Insidertransaktion11/17/2022
4Insidertransaktion11/17/2022
4Insidertransaktion11/17/2022
4Insidertransaktion11/8/2022
4Insidertransaktion11/8/2022
4Insidertransaktion11/8/2022
4Insidertransaktion11/8/2022
SC 13D/ASC 13D/A-Formular11/3/2022
SC 13D/ASC 13D/A-Formular10/28/2022
SC 13D/ASC 13D/A-Formular10/18/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/11/2022
4Insidertransaktion10/5/2022
4Insidertransaktion10/5/2022
4Insidertransaktion10/5/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/30/2022
DEFA14ADEFA14A-Formular9/30/2022
SC 13D/ASC 13D/A-Formular9/19/2022
SC 13DSC 13D-Formular9/19/2022
DEFM14ADEFM14A-Formular9/8/2022
SC 13D/ASC 13D/A-Formular9/7/2022
PREM14APREM14A-Formular8/25/2022
SC 13G/ABeneficial ownership report8/10/2022
10-QQuartalsbericht8/5/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/5/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/29/2022
DEFA14ADEFA14A-Formular7/8/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/7/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/7/2022
DEFA14ADEFA14A-Formular7/7/2022
DEFA14ADEFA14A-Formular7/7/2022
DEFA14ADEFA14A-Formular7/7/2022
DEFA14ADEFA14A-Formular7/7/2022
4Insidertransaktion6/28/2022
4Insidertransaktion6/24/2022
SDSD-Formular5/27/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/6/2022
10-QQuartalsbericht5/6/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/2/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/7/2022
4Insidertransaktion2/28/2022
4Insidertransaktion2/22/2022
33-Formular2/22/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/22/2022
4Insidertransaktion2/17/2022
SC 13G/ABeneficial ownership report2/11/2022
SC 13G/ABeneficial ownership report2/11/2022
SC 13G/ABeneficial ownership report2/10/2022
SC 13G/ABeneficial ownership report2/10/2022
SC 13DSC 13D-Formular2/4/2022
10-QQuartalsbericht2/4/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/4/2022
4Insidertransaktion1/28/2022

Meridian Bioscience Documents 2026

This page contains all official documents and SEC filings for Meridian Bioscience stock (VIVO, ISIN: US5895841014). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Meridian Bioscience's regulatory filings.

Meridian Bioscience Stock analysis

Meridian Bioscience Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support.